ArticleActa pharmacologica Sinica2021

ACSL4 is a predictive biomarker of sorafenib sensitivity in hepatocellular carcinoma.

Ji Feng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.